Skip to content
buyModerate cluster of 3

Sr One Capital Management, LLC bought $10.0M of AVLN

owner at Avalyn Pharma Inc.. 555,555 shares at an average of $18.00, traded May 1, 2026, filed May 1, 2026.

Conviction score
53
Value
$10.0M
555,555 shares
Holdings after
1,122,087
+29% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet

Score components

  • Role
    10% owner
    +12
  • Trade size
    $10.0M at market
    +25
  • Relative to holdings
    Holdings up 29%
    +6
  • Price context
    No price history yet
    0
  • Cluster
    3 insiders buying within 14 days
    +15
  • Repeat buying
    First buy in 90 days
    0
  • Track record
    Too few past buys to judge (0 with prices)
    0
  • Outside holder
    A 10% owner who is not an officer or director
    -5

What happened after comparable buys

Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.

This signal so far: 1m -3.6%, 3m -3.5%, 6m -.

Price around the trade, and since

From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.

AVLNOct 9, 2026 · close 25.76
Since filing May 1, 2026: -13.7%SPY +8.5% · excess -22.2%

Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™

Rows in this filing

Every transaction in Form 4 0001193125-26-201887, as filed. Open on EDGAR

DateTransactionSharesPriceValueHoldings afterFiled
May 1, 2026CConversion
Common Stockindirect: See Note 2
+1,419,298--1,419,298May 1, 2026
May 1, 2026CConversion
Common Stockindirect: See Note 2
+489,486--1,908,784May 1, 2026
May 1, 2026POpen-market purchase
Common Stockindirect: See Note 2
+277,778$18.00$5.0M2,186,562May 1, 2026
May 1, 2026CConversion
Common Stockindirect: See Note 4
+354,824--354,824May 1, 2026
May 1, 2026CConversion
Common Stockindirect: See Note 4
+489,486--844,310May 1, 2026
May 1, 2026POpen-market purchase
Common Stockindirect: See Note 4
+277,777$18.00$5.0M1,122,087May 1, 2026
May 1, 2026CConversion
Series C-1 Convertible Preferred Stockderivativeindirect: See Note 2
-27,309,719--0May 1, 2026
May 1, 2026CConversion
Series D Convertible Preferred Stockderivativeindirect: See Note 2
-9,418,561--0May 1, 2026
May 1, 2026CConversion
Series C-1 Convertible Preferred Stockderivativeindirect: See Note 4
-6,827,429--0May 1, 2026
May 1, 2026CConversion
Series D Convertible Preferred Stockderivativeindirect: See Note 4
-9,418,560--0May 1, 2026

Related signals

Other insiders at Avalyn Pharma Inc. and this insider’s other filings.

ScoreCompanyInsiderValueHoldingsFiled
50Moderate
AVLNbuy 3
Avalyn Pharma Inc.
Novo Holdings A/S
owner
$10.0M
555,555 shares
+17%
58Moderate
AVLNbuy 3
Avalyn Pharma Inc.
Jill Carroll
director
$5.0M
277,778 shares
+15%

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.

Sr One Capital Management, LLC bought $10.0M of AVLN | InsiderTell